CytoTerra Inc.
StreetZero Signal 59
About CytoTerra Inc.
CytoTerra Inc. provides next-generation oncology diagnostics through genome-wide cytogenetics with no special sample requirements. The company is headquartered in Seattle, WA and offers Genome Proximity Mapping technology. It operates in the medical and diagnostic laboratories industry as a privately held entity focused on cancer diagnostics and risk stratification.
LATEST FUNDINGPrivate Placement
$300K
Announced 2026-10-07
TOTAL RAISED$300,000
IN THE NEWS
EMPLOYEES6
FOUNDED—
HQSeattle, WA, United States
Industry
Other Technology
Tags
BiotechnologyOncology DiagnosticsCytogenetics
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- CytoTerra focuses on next-generation oncology diagnostics with genome-wide cytogenetics.
- Headquartered in Seattle, WA with 6 employees and leadership including CEO Stephen Eacker and Co-Founder Jesse Salk.
- Raised $300,000 in private placement with no disclosed investors.
- Platform enables comprehensive assays without special sample requirements for various cancer indications.
Ask StreetZero about CytoTerra Inc.
Put our AI to work on this deal.
Similar companies
Other Other Technology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account